BioPharmSignal logoBioPharmSignal

Biotech News

MIMEDX Announces Record Fourth Quarter and Full Year 2025 Operating and Financial Results

MiMedx (MDXG)MiMedxEarnings

Net Sales Grew 27% Year-Over-Year for the Fourth Quarter and 20% for the Full Year Fourth Quarter GAAP Net Income and Earnings Per Share were $15 million and $0.10, Respectively Fourth Quarter Adjusted EBITDA 1 was $29 Million, or 25% of Net Sales Company Estimates 2026 Net Sales in a Range of

Related news

MDXGMiMedx2026-02-17 13:00 EST

MIMEDX to Host Fourth Quarter and Full Year 2025 Operating and Financial Results Conference Call on February 25

MDXGMiMedx2026-07-20 12:00 EST

MIMEDX to Host Second Quarter 2026 Operating and Financial Results Conference Call on July 29

ADMAADMA Biologics2026-02-25 21:05 EST

ADMA Biologics Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

CHRSCoherus BioSciences, Inc.2026-03-09 20:15 EST

Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update

STTKShattuck Labs2026-03-05 11:15 EST

Shattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Highlights

CHRSCoherus BioSciences, Inc.2026-03-02 14:30 EST

Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026

RXRXRecursion2026-02-25 11:30 EST

Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

RXRXRecursion2026-02-18 13:30 EST

Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25

ADMAADMA Biologics2026-02-18 12:00 EST

ADMA Biologics to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

ENTXEntera Bio2026-08-07 20:05 EST

Entera Announces Second Quarter 2026 Financial Results and Business Updates

View all latest news

MiMedx

Placental Tissue Products MIMEDX develops and commercializes placental-tissue products for wound care, burns and surgery. Its processing and product portfolio are designed to provide extracellular-matrix and biologic materials that support healing and tissue repair. Wound-Care Portfolio The company has more than a decade of experience...

Recent company news

MDXGMiMedx2026-07-29 20:07 EST

MIMEDX Announces Second Quarter 2026 Operating & Financial Results

MDXGMiMedx2026-07-29 20:01 EST

MIMEDX to Acquire Sanara MedTech

MDXGMiMedx2026-07-20 12:00 EST

MIMEDX to Host Second Quarter 2026 Operating and Financial Results Conference Call on July 29

MDXGMiMedx2026-05-21 12:45 EST

MIMEDX to Participate in Craig-Hallum 23rd Annual Institutional Investor Conference

MDXGMiMedx2026-05-08 12:00 EST

MIMEDX Announces Launch of G4Derm® Plus

Stock data

Close
4.18 USD
Market cap
531.74M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States